271 related articles for article (PubMed ID: 22172949)
1. Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy.
Glascock JJ; Shababi M; Wetz MJ; Krogman MM; Lorson CL
Biochem Biophys Res Commun; 2012 Jan; 417(1):376-81. PubMed ID: 22172949
[TBL] [Abstract][Full Text] [Related]
2. Defining the therapeutic window in a severe animal model of spinal muscular atrophy.
Robbins KL; Glascock JJ; Osman EY; Miller MR; Lorson CL
Hum Mol Genet; 2014 Sep; 23(17):4559-68. PubMed ID: 24722206
[TBL] [Abstract][Full Text] [Related]
3. Decreasing disease severity in symptomatic, Smn(-/-);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery.
Glascock JJ; Osman EY; Wetz MJ; Krogman MM; Shababi M; Lorson CL
Hum Gene Ther; 2012 Mar; 23(3):330-5. PubMed ID: 22029744
[TBL] [Abstract][Full Text] [Related]
4. Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy.
Reilly A; Deguise MO; Beauvais A; Yaworski R; Thebault S; Tessier DR; Tabard-Cossa V; Hensel N; Schneider BL; Kothary R
Gene Ther; 2022 Sep; 29(9):544-554. PubMed ID: 35462564
[TBL] [Abstract][Full Text] [Related]
5. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.
Dominguez E; Marais T; Chatauret N; Benkhelifa-Ziyyat S; Duque S; Ravassard P; Carcenac R; Astord S; Pereira de Moura A; Voit T; Barkats M
Hum Mol Genet; 2011 Feb; 20(4):681-93. PubMed ID: 21118896
[TBL] [Abstract][Full Text] [Related]
6. Restoration of SMN to Emx-1 expressing cortical neurons is not sufficient to provide benefit to a severe mouse model of Spinal Muscular Atrophy.
Taylor AS; Glascock JJ; Rose FF; Lutz C; Lorson CL
Transgenic Res; 2013 Oct; 22(5):1029-36. PubMed ID: 23512182
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
[TBL] [Abstract][Full Text] [Related]
8. Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy.
Coady TH; Lorson CL
J Neurosci; 2010 Jan; 30(1):126-30. PubMed ID: 20053895
[TBL] [Abstract][Full Text] [Related]
9. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.
Passini MA; Bu J; Richards AM; Treleaven CM; Sullivan JA; O'Riordan CR; Scaria A; Kells AP; Samaranch L; San Sebastian W; Federici T; Fiandaca MS; Boulis NM; Bankiewicz KS; Shihabuddin LS; Cheng SH
Hum Gene Ther; 2014 Jul; 25(7):619-30. PubMed ID: 24617515
[TBL] [Abstract][Full Text] [Related]
10. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
Chen TH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
[TBL] [Abstract][Full Text] [Related]
11. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
[TBL] [Abstract][Full Text] [Related]
12. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.
Meyer K; Ferraiuolo L; Schmelzer L; Braun L; McGovern V; Likhite S; Michels O; Govoni A; Fitzgerald J; Morales P; Foust KD; Mendell JR; Burghes AH; Kaspar BK
Mol Ther; 2015 Mar; 23(3):477-87. PubMed ID: 25358252
[TBL] [Abstract][Full Text] [Related]
13. AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy.
Villalón E; Kline RA; Smith CE; Lorson ZC; Osman EY; O'Day S; Murray LM; Lorson CL
Hum Mol Genet; 2019 Nov; 28(22):3742-3754. PubMed ID: 31363739
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice.
Benkhelifa-Ziyyat S; Besse A; Roda M; Duque S; Astord S; Carcenac R; Marais T; Barkats M
Mol Ther; 2013 Feb; 21(2):282-90. PubMed ID: 23295949
[TBL] [Abstract][Full Text] [Related]
15. Long term peripheral AAV9-SMN gene therapy promotes survival in a mouse model of spinal muscular atrophy.
Reilly A; Yaworski R; Beauvais A; Schneider BL; Kothary R
Hum Mol Genet; 2024 Feb; 33(6):510-519. PubMed ID: 38073249
[TBL] [Abstract][Full Text] [Related]
16. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
[TBL] [Abstract][Full Text] [Related]
17. Moving towards treatments for spinal muscular atrophy: hopes and limits.
Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
[TBL] [Abstract][Full Text] [Related]
18. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
Kannan A; Jiang X; He L; Ahmad S; Gangwani L
Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288
[TBL] [Abstract][Full Text] [Related]
19. Therapeutics development for spinal muscular atrophy.
Sumner CJ
NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
[TBL] [Abstract][Full Text] [Related]
20. AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice.
Besse A; Astord S; Marais T; Roda M; Giroux B; Lejeune FX; Relaix F; Smeriglio P; Barkats M; Biferi MG
Mol Ther; 2020 Aug; 28(8):1887-1901. PubMed ID: 32470325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
